Meta-analysis shows targeted radiation therapy may be as effective as standard care for small cell lung cancer patients

Credit: Unsplash/CC0 Public Domain

A study published in The Lancet Oncology suggests that a targeted radiation therapy is equitable to the current standard of care for patients whose lung cancer has metastasized to the brain.

The work, led by researchers at St. Michael's Hospital, a site of Unity Health Toronto, suggests that implementation of this targeted approach, which is known to result in fewer negative cognitive consequences for patients, could potentially improve their care experience.

For patients with small cell , a fast-growing disease that develops in the tissues of the lungs and often spreads to other parts of the body, is currently treated with whole brain radiation therapy, which targets the entire brain. While this approach treats even microscopic tumors, it results in memory problems and decreases cognitive function. The alternative which spares healthy brain tissue by precisely targeting the tumor, called , has been shown to have less severe cognitive consequences but has not yet been studied in patients with whose disease has spread to the brain.

"For many years, it made sense to treat these patients with whole brain radiation because their survival was quite poor," said Karolina Gaebe, a research student in Dr. Sunit Das's lab, who led the study. Dr. Das is a scientist at the Keenan Research Center for Biomedical Science and a neurosurgical oncologist at St. Michael's Hospital in Toronto.

"For them, long-term consequences of the treatment were not as crucial as reducing the impact of disease in the short-term. But now, as treatments for their lung cancer have improved, these patients are surviving much longer."

Dr. Das, Gaebe, and their team set out to learn more after noticing patients with longer survival times were also living with severe cognitive impairments due to the treatments for their brain metastases. They wanted to understand whether a more targeted brain radiation regimen might be as beneficial for these patients, similar to what has already been shown in most other cancer types.

As a first step, they undertook this meta-analysis, reviewing current literature to examine survival and brain outcomes following stereotactic radiosurgery for patients with small cell lung cancer that had spread to the brain. The team analyzed data from 31 studies and included 18,130 patients, the largest cohort of small cell cancer patients with brain metastases to be studied so far.

The team's next goal is to launch a large, comprehensive clinical trial and explore the differences in cognitive outcomes between stereotactic radiosurgery and whole brain radiation therapy in this patient population.

"Because this is a , we can't use this as absolute evidence that all patients should be treated in this way," Dr. Das said. "But essentially, this means that we need to challenge our standing worldwide paradigms for treating patients with this disease and revisit the idea that these should receive whole radiation therapy."

More information: Karolina Gaebe et al, Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis, The Lancet Oncology (2022). DOI: 10.1016/S1470-2045(22)00271-6

Journal information: Lancet Oncology
Citation: Meta-analysis shows targeted radiation therapy may be as effective as standard care for small cell lung cancer patients (2022, May 27) retrieved 22 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New brain cancer guidelines to improve care, patient survival


Feedback to editors